Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer.
Aikaterini ChatzipliHervé R BonnefoiGaetan MacGroganJulie SentisDavid CameronCoralie Poncetnull nullRichard IggoPublished in: British journal of cancer (2021)
We found no evidence that expansion of clones containing recurrent oncogenic driver mutations is responsible for resistance to neoadjuvant chemotherapy. The persistence of classic oncogenic mutations in pathways for which targeted therapies are now available highlights their importance as drug targets in patients who have failed chemotherapy but provides no support for a direct role of driver oncogenes in resistance to chemotherapy. CLINICALTRIALS.GOV: EORTC 10994/BIG 1-00 Trial registration number NCT00017095.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- estrogen receptor
- rectal cancer
- lymph node
- sentinel lymph node
- squamous cell carcinoma
- end stage renal disease
- radiation therapy
- newly diagnosed
- chronic kidney disease
- ejection fraction
- transcription factor
- clinical trial
- prognostic factors
- emergency department
- study protocol
- phase ii
- randomized controlled trial
- copy number
- phase iii
- machine learning
- patient reported
- open label
- young adults
- adverse drug
- placebo controlled